share_log

HC Wainwright & Co. Reiterates Buy on Acrivon Therapeutics, Maintains $20 Price Target

Benzinga ·  Apr 25 07:29

HC Wainwright & Co. analyst Emily Bodnar reiterates Acrivon Therapeutics (NASDAQ:ACRV) with a Buy and maintains $20 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment